Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Pericarditis III: Medical Management

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

Myocarditis IV: Nursing Management

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026

Same author

A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis.

Seminars in arthritis and rheumatism·2026

Same author

Pulmonary manifestations of granulomatosis with polyangiitis and microscopic polyangiitis.

Seminars in arthritis and rheumatism·2026

Same author

ACR Presidential Address: The American College of Rheumatology in 2025 - The Strength, Resilience, and Importance of Our Rheumatology Community.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Same author

Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis.

Nature reviews. Rheumatology·2025

Same author

Large-vessel vasculitis.

Lancet (London, England)·2025

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Small-vessel vasculitis: therapeutic management.

Carol A Langford¹

¹Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH 44195, USA. langfoc@ccf.org

Current Rheumatology Reports

|August 11, 2007

Summary

Small-vessel vasculitis involves inflammation of small blood vessels. Current treatments like prednisone and cyclophosphamide are toxic and don't prevent relapse, prompting research into safer alternatives and biologic agents.

Area of Science:

Rheumatology
Immunology
Internal Medicine

Background:

Small-vessel vasculitis is characterized by inflammation of arterioles, venules, or capillaries.
Commonly associated with conditions like Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome.
Current treatments, while effective for remission and survival, involve toxic regimens and do not prevent relapse.

Purpose of the Study:

To review current therapeutic approaches for small-vessel vasculitis.
To highlight the limitations of existing treatments, including toxicity and relapse rates.
To explore emerging treatment strategies, such as modified cyclophosphamide use and biologic agents.

Main Methods:

Literature review of current therapeutic strategies for small-vessel vasculitis.

More Related Videos

Rodent Inferior Vena Cava Venoplasty Balloon Model

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Related Experiment Videos

Last Updated: Jul 13, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Rodent Inferior Vena Cava Venoplasty Balloon Model

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Analysis of treatment efficacy, toxicity, and relapse rates.

Examination of emerging clinical trials and novel therapeutic agents.

Main Results:

Prednisone and cyclophosphamide can induce remission and prolong survival but are associated with significant toxicity and relapse.
Therapeutic strategies are evolving to minimize cyclophosphamide exposure.
Staged induction-maintenance regimens and alternative induction agents for nonsevere disease are being investigated.
Biologic agents represent a promising area for new treatment options.

Conclusions:

Optimizing treatment for small-vessel vasculitis requires balancing efficacy with reduced toxicity.
Minimizing cyclophosphamide exposure is a key goal in current therapeutic development.
Emerging biologic therapies hold potential for improved management of small-vessel vasculitis.